Vis børsmeldingen
DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.
THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES
DESCRIBED HEREIN. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS
ANNOUNCEMENT.
Reference is made to the stock exchange announcement published by Observe
Medical ASA (the “Company”) on 22 November 2023 regarding the approval by the
extraordinary general meeting of the Company of a rights issue of minimum
69,230,770 new shares and maximum 211,538,461 new shares (“Offer Shares”) in the
Company, each with a nominal value of NOK 0.26, at a subscription price of NOK
0.26 per Offer Share (the “Rights Issue”).
Reference is further made to the stock exchange announcement published on 24
November 2023 regarding the approval by the Financial Supervisory Authority of
Norway (Nw. Finanstilsynet) of the prospectus prepared by the Company (the
“Prospectus”) for the offer and listing on the Oslo Stock Exchange (Euronext
Expand) of up to 211,538,461 Offer Shares in the Rights Issue. Subject to
applicable local securities laws, the Prospectus, including the subscription
form for the Rights Issue, is made available at the Company’s website
(www.observemedical.com), as well as the website of SpareBank 1 Markets
(www.sb1markets.no).
The subscription period for the Rights Issue will commence today, on 28 November
2023, at 09:00 hours (CET) and expire on 12 December 2023 at 16:30 hours (CET)
(the “Subscription Period”). The Subscription Rights (as defined below) will be
tradable on the Oslo Stock Exchange (Euronext Expand) under the ticker code
“OBSRT” from today, 28 November 2023, at 09:00 hours (CET) until 6 December 2023
at 16:30 hours (CET).
Allocation of Subscription Rights:
Shareholders of the Company as of 22 November 2023 (and being registered as such
in Euronext Securities Oslo, the Norwegian Central Securities Depository (ESO)
as of 24 November 2023 pursuant to the two days’ settlement procedure of ESO
(the “Record Date”, and such shareholders, the “Existing Shareholders”)), have
been granted tradable subscription rights (the “Subscription Rights”) in the
Rights Issue.
Each Existing Shareholder has been granted 3.9546 Subscription Rights for each
existing share in the Company registered as held by the Existing Shareholder of
the Record Date, rounded down to the nearest whole Subscription Right. Each
Subscription Right will, subject to applicable law, give the right to subscribe
for, and be allocated one (1) new share at the subscription price. Over
-subscription and subscription without subscription rights are permitted.
The grant to, or acquisition of Subscription Rights and the subscription of
Offer Shares by persons resident in, or who are citizens of countries other than
Norway, may be affected by the laws of the relevant jurisdiction. For a further
description of such restrictions, reference is made to the introductory part on
page (i)-(iii) and Section 14 “Selling and Transfer Restrictions” of the
Prospectus.
Subscription Rights:
The Subscription Rights will be listed and tradable on Oslo Stock Exchange
(Euronext Expand) from 09:00 hours (CET) on 28 November 2023 to 16:30 hours
(CET) on 6 December 2023 under the ticker code “OBSRT”. The Subscription Rights
will hence only be tradable during a part of the Subscription Period.
Subscription Rights that are (i) not sold within 6 December 2023 at 16:30 hours
(CET) or (ii) not used to subscribe for shares in the Rights Issue prior to
expiry of the Subscription Period on 12 December 2023 at 16:30 hours (CET) will
lapse without compensation to the holder, and thus be without value.
The Subscription Rights are expected to have an economic value if the Company’s
shares trade above the subscription price during the Subscription Period.
Existing Shareholders who do not exercise their Subscription Rights will
experience a dilution of their shareholding in the Company. See Section 13.9
“Subscription Rights” and 13.30 “Dilution” in the Prospectus for further
information.
Subscription price:
NOK 0.26 per Offer Share.
Payment:
The payment date in the Rights Issue is 15 December 2023. In 2023 the Company
has received loans from its largest shareholders (listed in Appendix 3
(“Lenders”) in the minutes from the extraordinary general meeting held on 22
November 2023) with an aggregate nominal value of NOK 16.75 million, and NOK
20.186 million included accrued interest and interest that will accrue up to and
including the agreed maturity date. As previously announced by the Company, the
Lenders may choose to utilize the Loans (including accrued and unaccrued
interest calculated up to and including the agreed maturity date) fully or
partly to set-off against the subscription price to be paid upon any
subscription of shares in the Company during the terms of the Loans. As a
result, the subscription amount for the Offer Shares may be settled by both cash
and by way of set-off against shareholder loans.
Subject to (i) timely payment (in case of cash settlement) of the Offer Shares
subscribed for and allocated in the Rights Issue, and (ii) the remaining
conditions for completion (described below) being fulfilled, the Company expects
that the share capital increase pertaining to the Rights Issue will be
registered with the Norwegian Register of Business Enterprises on or about 21
December 2023, and that issuance and delivery of the Offer Shares pertaining to
the Rights Issue is completed on or about 22 December 2023. The Offer Shares are
expected to commence trading on the Oslo Stock Exchange (Euronext Expand) on 22
December 2023.
Subscription procedure:
In order to subscribe for Offer Shares, investors holding Subscription Rights
need to complete the subscription form and submit it to the Manager (as defined
below) at the address or email address set out in the Prospectus and in the
subscription form before 16:30 hours (CEST) on 12 December 2023. The
Subscription Form can be found in Appendix A in the Prospectus.
Subscribers who are Norwegian residents with a Norwegian personal identification
number who wish to subscribe for Offer Shares are encouraged to do so through
the VPS online subscription system (or by following the link on
www.sb1markets.no, which will redirect the subscriber to the VPS online
subscription system).
Conditions for completion of the Rights Issue:
The completion of the Rights Issue is subject to (i) the Company raising gross
proceeds in the Rights Issue of minimum NOK 18,000,000.20 in cash and (ii) that
each of the Lenders convert the Loans in whole and/or enter into an amendment
agreement for the remaining amount under each of the respective Loans that are
not converted regarding extension of the maturity date and amendment of the
terms to market terms.
If it becomes clear that the conditions mentioned above will not be fulfilled,
the Rights Issue will be withdrawn. Further, the Rights Issue may be withdrawn,
or the completion of the Rights issued may be delayed, if the aggregate minimum
subscription amount for the Offer Shares is not received by the Company on time
or at all.
If the Rights Issue is withdrawn, all Subscription Rights will lapse without
value, any subscriptions for, and allocations of, Offer Shares that have been
made will be disregarded and any payments for Offer Shares made will be returned
to the subscribers without interest or any other compensation. The lapsing of
Subscription Rights will be without prejudice to the validity of any trades in
Subscription Rights, and investors will not receive any refund or compensation
in respect of Subscription Rights purchased in the market.
SpareBank 1 Markets is acting as manager in the Rights Issue (the “Manager”).
Advokatfirmaet Thommessen AS is acting as legal counsel to the Company in
relation to the Rights Issue.
For further information about the Company, please contact:
Rune Nystad, CEO Observe Medical
Mobile: +47 916 24 683
E-mail: rune.nystad@observemedical.com
Per Arne Nygård, CFO Observe Medical
Mobile: +47 411 04 345
E-mail: perarne.nygard@observemedical.com
This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.
About Observe Medical
Observe Medical is a Nordic medtech company that develops, markets and sells
innovative medtech products for the global market. The Company is committed to
improving patient welfare and patient outcomes, improving clinical data accuracy
and promoting positive health economics.
The Company seeks to drive growth by leveraging its expertise in sales and
commercialization of its broad portfolio of medical technology products, mainly
in urine measurement, ultrasound, anesthesiology/ICUs, surgery and wound care,
in combination with targeted M&A.
The Company is headquartered in Oslo, Norway, with additional offices in Narvik,
Norway and Gothenburg, Sweden, and subsidiaries in Finland and the US. In
addition, Observe Medical has a direct sale organization in the Nordics and a
distributor network internationally.
Further information is available at www.observemedical.com.
This announcement does not constitute an offer of securities for sale or a
solicitation of an offer to purchase securities of the Company in the United
States or any other jurisdiction. Copies of this document may not be sent to
jurisdictions, or distributed in or sent from jurisdictions, in which this is
barred or prohibited by law. The securities of the Company may not be offered or
sold in the United States absent registration or an exemption from registration
under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”).
The securities of the Company have not been, and will not be, registered under
the U.S. Securities Act. Any sale in the United States of the securities
mentioned in this communication will be made solely to “qualified institutional
buyers” as defined in Rule 144A under the U.S. Securities Act. No public
offering of the securities will be made in the United States.
Any offering of the securities referred to in this announcement will be made by
means of a prospectus (the “Prospectus”) which was approved by the Norwegian
Financial Supervisory Authority on 24 November 2023. This announcement is an
advertisement and is not a prospectus for the purposes of Regulation (EU)
2017/1129 of the European Parliament and of the Council of 14 June 2017 on
prospectuses to be published when securities are offered to the public or
admitted to trading on a regulated market, and repealing Directive 2003/71/EC
(as amended) as implemented in any EA Member State (the “Prospectus
Regulation”). Investors should not subscribe for any securities referred to in
this announcement except on the basis of information contained in the
Prospectus. Copies of the Prospectus is available from the Company’s registered
office and, subject to certain exceptions, on the websites of the Manager and
the Company.
In any EEA Member State, this communication is only addressed to and is only
directed at qualified investors in that Member State within the meaning of the
Prospectus Regulation, i.e., only to investors who can receive the offer without
an approved prospectus in such EEA Member State.
In the United Kingdom, this communication is only addressed to and is only
directed at Qualified Investors who (i) are investment professionals falling
within Article 19(5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005 (as amended) (the “Order”) or (ii) are persons falling
within Article 49(2)(a) to (d) of the Order (high net worth companies,
unincorporated associations, etc.) (all such persons together being referred to
as “Relevant Persons”). These materials are directed only at Relevant Persons
and must not be acted on or relied on by persons who are not Relevant Persons.
Any investment or investment activity to which this announcement relates is
available only to Relevant Persons and will be engaged in only with Relevant
Persons. Persons distributing this communication must satisfy themselves that it
is lawful to do so.
This document is not for publication or distribution in, directly or indirectly,
Australia, Canada, Japan, the United States or any other jurisdiction in which
such release, publication or distribution would be unlawful, and it does not
constitute an offer or invitation to subscribe for or purchase any securities in
such countries or in any other jurisdiction. In particular, the document and the
information contained herein should not be distributed or otherwise transmitted
into the United States or to publications with a general circulation in the
United States of America.
The Manager is acting for the Company in connection with the Rights Issue and no
one else and will not be responsible to anyone other than the Company for
providing the protections afforded to their respective clients or for providing
advice in relation to the Rights Issue or any transaction or arrangement
referred to in this announcement.
Matters discussed in this announcement may constitute forward-looking
statements. Forward-looking statements are statements that are not historical
facts and may be identified by words such as “anticipate”, “believe”,
“continue”, “estimate”, “expect”, “intends”, “may”, “should”, “will” and similar
expressions. The forward-looking statements in this release are based upon
various assumptions, many of which are based, in turn, upon further assumptions.
Although the Company believes that these assumptions were reasonable when made,
these assumptions are inherently subject to significant known and unknown risks,
uncertainties, contingencies and other important factors which are difficult or
impossible to predict and are beyond its control. Such risks, uncertainties,
contingencies and other important factors could cause actual events to differ
materially from the expectations expressed or implied in this release by such
forward-looking statements. The information, opinions and forward-looking
statements contained in this announcement speak only as at its date and are
subject to change without notice. This announcement is made by and is the
responsibility of, the Company. Neither the Manager nor any of its affiliates
makes any representation as to the accuracy or completeness of this announcement
and none of them accepts any responsibility for the contents of this
announcement or any matters referred to herein.
This announcement is for information purposes only and is not to be relied upon
in substitution for the exercise of independent judgment. It is not intended as
investment advice and under no circumstances is it to be used or considered as
an offer to sell, or a solicitation of an offer to buy any securities or a
recommendation to buy or sell any securities of the Company. No reliance may be
placed for any purpose on the information contained in this announcement or its
accuracy, fairness or completeness. Neither the Manager nor any of its
affiliates accepts any liability arising from the use of this announcement.
Kilde
